READ-ONLY DIGITIZATION RESULT
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.
J Clin Oncol · 2026-Jan-20 · PMID 41365333
Panel B质量警告待 EXE 对齐验证
DFS
FIG A3. Kaplan-Meier plot of DFS curve stratified by (A) age at diagnosis and (B) HER2 status. HER2-low indicated tumors with HER2 IHC status 1+ to 2+. Cb, carboplatin; DFS, disease-free survival; EC-T, epirubicin plus cyclophosphamide followed by taxanes; EC-TCb, EC-T plus carboplatin; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
| Curve | 序号 | X (norm) | Y (norm) | X (real) | Y (real) | X (pixel) | Y (pixel) |
|---|---|---|---|---|---|---|---|
| 1 | 1 | 0.0000 | 0.6640 | -1.0000 | 0.4980 | 186 | 243 |
| 1 | 2 | 0.0421 | 0.6640 | -0.5578 | 0.4980 | 260 | 243 |
| 1 | 3 | 0.0427 | 0.6640 | -0.5518 | 0.4980 | 261 | 243 |
| 1 | 4 | 0.0433 | 0.6619 | -0.5458 | 0.4964 | 262 | 244 |
| 1 | 5 | 0.0438 | 0.6660 | -0.5398 | 0.4995 | 263 | 242 |
| 1 | 6 | 0.0444 | 0.6660 | -0.5339 | 0.4995 | 264 | 242 |
| 1 | 7 | 0.0450 | 0.6660 | -0.5279 | 0.4995 | 265 | 242 |
| 1 | 8 | 0.0455 | 0.6660 | -0.5219 | 0.4995 | 266 | 242 |
| 1 | 9 | 0.0461 | 0.3340 | -0.5159 | 0.2505 | 267 | 405 |
| 1 | 10 | 0.0467 | 0.3238 | -0.5100 | 0.2429 | 268 | 410 |
| 1 | 11 | 0.3756 | 0.3462 | 2.9442 | 0.2597 | 846 | 399 |
| 1 | 12 | 0.3762 | 0.3462 | 2.9502 | 0.2597 | 847 | 399 |
| 1 | 13 | 0.3768 | 0.1711 | 2.9562 | 0.1283 | 848 | 485 |
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-24T15:14:48+00:00 |